MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hope for rare blood cancer: new combo trial targets tough cases
Disease control Recruiting nowThis study tests whether adding iadademstat to the standard drug ASTX727 works better than ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 62 adults whose disease has progressed to a more aggressive phase will be ra…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:56 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental oral drug called LP-118 in up to 100 adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors …
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
New hope for blood cancer patients: experimental drug enters human trials
Disease control Recruiting nowThis study is testing a new drug called BGB-11417 for people with certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The goal is to find the safest dose and see if the drug works on its own or when combined with another cancer medic…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 26, 2026 06:44 UTC
-
New immune cell therapy aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis early-phase study tests a new treatment for adults with acute myeloid leukemia or myelodysplastic syndrome who still have small amounts of cancer cells after standard therapy. The treatment uses a patient's own blood cells that are specially armed with a bispecific antibody …
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: University of Virginia • Aim: Disease control
Last updated May 26, 2026 06:43 UTC
-
New combo aims to boost transplant success in rare blood cancers
Disease control Recruiting nowThis study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 a…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 06:42 UTC
-
Immune boosting NK cells show promise in blood cancer trial
Disease control Recruiting nowThis study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Metal detox may boost chemo in tough blood cancers
Disease control Recruiting nowThis early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for rare blood cancers: drug combo trial opens
Disease control Recruiting nowThis study tests a new drug called axatilimab, alone or with another drug (azacitidine), for people with advanced blood cancers like MPN, MPN/MDS overlap, or high-risk CMML. Axatilimab is an antibody that blocks a protein on white blood cells to slow cancer growth. The trial aims…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New combo therapy aims to make bone marrow transplants safer for older blood cancer patients
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard transplant care can prevent a serious side effect called graft-versus-host disease (GVHD) in older adults with myelofibrosis or related blood cancers. About 50 participants will receive ruxolitinib before, during, a…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Can a clot-preserving drug stop bleeding in blood cancers?
Symptom relief Recruiting nowThis study tests whether tranexamic acid, a medicine that helps blood clots stay in place, can reduce bleeding in people with myelodysplastic syndromes or acute myeloid leukemia who are on chemotherapy. About 75 adults with low platelet counts will be randomly assigned to receive…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE2 • Sponsor: University of Manitoba • Aim: Symptom relief
Last updated May 26, 2026 06:45 UTC
-
Telehealth tool aims to ease tough talks for older blood cancer patients
Knowledge-focused Recruiting nowThis study tests a telehealth program to help older patients (60+) with blood cancers like leukemia and MDS communicate better with their doctors and complete advance care plans. About 207 patients and their caregivers will be randomly assigned to the program or usual care. The g…
Matched conditions: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: NA • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated May 20, 2026 11:54 UTC